Adverse Events and Safety Outcomes Associated With Chemotherapy for Inflammatory Bowel Disease–associated Gastrointestinal Cancers

Chemotherapy, including chemoradiotherapy, can be safely administered to patients with inflammatory bowel disease-associated gastrointestinal cancer with careful management. In Crohn's disease-associated cancer, residual small intestinal length is a key factor in predicting gastrointestinal toxicity severity, particularly diarrhea. Individualized dose adjustments and close monitoring are essential to balance cancer treatment efficacy with the unique risks associated with inflammatory bowel disease.